



항암화학요법으로 완전 관해 되었던 위암환자에서 10년 후 새롭게 발생한 원발성 식도암 및 대장암 증례

고신대학교 복음병원 소화기내과
조대현, 박선자, 김재현, 정경원, 김성은, 문원, 박무인

Patient Information (1st admission)

- 85/M
- **Chief Complaint**
 - Dizziness
- **Present Illness**
 - 2010. 2월, Dizziness onset
 - 2010. 8월, 종합검진 상, gastric ulcer로 한달간 medication
 - 2010. 9월 7일 F/U EGD 시행 후, 심한 빈혈을 동반한 Malignancy 의심되어 전원



Patient Information

Past History

DM(-)/HTN(+)

Pul. Tbc(-)/hepatitis(-)/cancer(-)

Hyperlipidemia(-)

Review of System

Dizziness (+) Weight loss (-)

Nausea (-) Vomiting (-)

Diarrhea (-) Constipation (-)

Abdominal pain (-)

Melena (-) Hematochezia (-)

Physical examination

V/S 130/80-72-20-36.9

Anemic conjunctiva (+)

Abdomen

Soft and mild distension

No rebound

Lab

Hb/WBC/PLT 4.8/7300/365000

BUN/Cr/Na/K 18.6/0.58/142/3.9





AST/ALT/CRP 13/17/0.1

CA19-9 634.2



H.pylori Ab, Ig G Pos(1.31)



2010년 9월 초진 당시 위내시경 소견



2010년 9월 초진 당시 복부 CT 및 PET-CT 소견







최종 진단:


**Gastric cancer with multiple LN meta
(Borrmann type 1, Papillary ADC)**

-> FOLFOX CTx 시작(2010.09.18.)

2011년 1월, 6회 FOLFOX 치료 후 호전된 위내시경 소견



2011년 1월, 6회 FOLFOX 치료 후 호전된 복부 CT 및 PET-CT 소견







2011년 1월, 6회 FOLFOX 치료 후 치료방향.



- Gastric cancer improved state
 - 외과와의 협진 통하여 수술 진행 고려.
 - 환자, 보호자의 거절로 CTx. 지속하기로 하여 7th FOLFOX 진행 후 퇴원.




2013년 2월 14일 CTx 종료 후 **follow up** 당시 위내시경 소견



2013년 2월 14일 CTx 종료 후 **follow up** 당시 복부 CT 및 PET-CT 소견



2010년 9월부터 2013년 7월까지 CA 19-9의 변화






2021년 7월 re-admission

- 85/M
- **Chief Complaint**
 - for W/U
- **Present Illness**
 - 2021.7.5. 식도의 SCC 진단되어 Evaluation 위해 내원.



2021년 7월 실시한 식도위내시경 검사 소견





2021년 7월 실시한 대장내시경 소견

조직 소견

- pT1N0(0/12)
ADC m/d
submucosal invasion
-> 3000micrometer
from M.M



2021년 7월 PET-CT 소견



Gastric cancer with
multiple LN meta
(Borrmann type 1,
Papillary ADC)



24th CTx. 후 CTx. 종료
(11.12.25.)



2015. 이후 f/u loss



2021.7.
esophageal cancer
발견되어 내원.



Ca. w/u




Esophageal ca.
superficial type 0-
IIa(SCC)
&
Colon ca.(ADC m/d)

Without metastasis

최종 진단

- 1. Esophageal ca. superficial type 0-IIa(SCC)**
- 2. Colon ca.(ADC m/d) without metastasis**




2021년 8월12일 Esophageal ESD c Lt. hemicolectomy 시행







ESD - lamina propria, well to m/d(M2)


Lt. Hemicolectomy Specimen



조직 소견

- No residual malignancy & lymph node metastasis





저널 리뷰

A phase II study of modified FOLFOX as first-line chemotherapy for metastatic gastric cancer in elderly patients with associated diseases

**Vincenzo Catalano · Renato Bissoni · Francesco Graziano · Paolo Giordani ·
Paolo Alessandroni · Anna Maria Baldelli · Virginia Casadei · David Rossi ·
Stefano Luzi Fedeli · Silvia D’Emidio · Lucio Giustini · Giammaria Fiorentini**

Received: 17 July 2012 / Accepted: 23 September 2012 / Published online: 11 October 2012
© The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2012

Table 3 Objective tumor response rates in advanced untreated elderly gastric cancer patients ($n = 43$), according to RECIST

Response	Number (%)
Complete response	3 (7.0)
Partial response	12 (27.9)
ORR (95 % CI)	34.9 (20.6–49.1)
Stable disease	15 (34.9)
Progressive disease	11 (25.6)
Not assessable	2 (4.6)

CI confidence interval, *ORR* overall response rate, *RECIST* Response Evaluation Criteria in Solid Tumors




Fig. 1 Kaplan–Meier curve of progression-free survival ($n = 43$)




Fig. 2 Kaplan–Meier curve of overall survival ($n = 43$)

Second Primary Cancers After Gastric Cancer, and Gastric Cancer as Second Primary Cancer

Guoqiao Zheng ¹⁻³
Kristina Sundquist ³⁻⁵
Jan Sundquist ³⁻⁶
Tianhui Chen ⁷
Asta Försti ^{1,3,8,9}
Akseli Hemminki ^{10,11}
Kari Hemminki ^{1-3,12}

Clinical Epidemiology 2021:13 515–525

515



© 2021 Zheng et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at <https://www.dovepress.com/terms.php> and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (<http://creativecommons.org/licenses/by-nc/3.0/>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (<https://www.dovepress.com/terms.php>).

Gastric Cancer	Cancer	SPC After Gastric Cancer			
		N	SIR	95% CI	
Cardia	UAT	3	0.63	0.12	1.87
	Esophagus	17	6.64	3.86	10.65
	Gastric, non-cardia	3	0.62	0.12	1.82
	Small intestine	3	3.10	0.58	9.16
	CRC	19	0.72	0.43	1.12
	Liver	3	0.54	0.10	1.60
	Pancreas	3	0.54	0.10	1.61
	Lung	11	0.58	0.29	1.03
	Breast	9	0.99	0.45	1.88
	Cervix				
	Endometrium	1	0.44	0	2.54
	Ovary	1	0.79	0	4.53
	Female genitals				
	Prostate	36	0.55	0.39	0.77
	Testis				
	Male genitals				

Male genitals				
Kidney	5	1.33	0.42	3.13
Bladder	13	0.95	0.51	1.64
Melanoma	7	1.01	0.40	2.09
Skin SCC	5	0.37	0.12	0.87
Nervous system	3	0.79	0.15	2.33
Thyroid	3	4.17	0.79	12.35
Endocrine	2	1.05	0.10	3.86
Connective tissue				
NHL	8	1.14	0.49	2.25
Myeloma				
Leukemia	5	0.80	0.25	1.87
All	170	0.83	0.71	0.97



Gastric Cancer	Cancer	SPC After Gastric Cancer			
		N	SIR	95% CI	
Non-cardia	UAT	18	0.90	0.53	1.43
	Esophagus	11	1.05	0.52	1.88
	Gastric, cardia	6	1.04	0.37	2.27
	Small intestine	19	4.34	2.61	6.8
	CRC	150	1.17	0.99	1.37
	Liver	24	0.89	0.57	1.33
	Pancreas	26	1.01	0.66	1.48
	Lung	67	0.82	0.63	1.04
	Breast	70	0.95	0.74	1.2
	Cervix	5	1.23	0.39	2.89
	Endometrium	13	0.68	0.36	1.16
	Ovary	11	1.04	0.52	1.87
	Female genitals	3	0.8	0.15	2.37
	Prostate	177	0.75	0.64	0.87
	Testis	1	1.66	0	9.53
	Male genitals	1	0.47	0	2.72

Testis	1	1.66	0
Male genitals	1	0.47	0
Kidney	27	1.68	1.11
Bladder	48	0.83	0.61
Melanoma	19	0.64	0.38
Skin SCC	66	0.91	0.7
Nervous system	9	0.55	0.25
Thyroid	5	1.31	0.41
Endocrine	10	1.04	0.50
Connective tissue	6	1.15	0.41
NHL	26	0.80	0.52
Myeloma	6	0.41	0.15
Leukemia	25	0.87	0.56
All	880	0.93	0.87



경청해 주셔서 감사합니다.

